PeptiDream Inc. (TYO:4587)
1,029.50
-3.00 (-0.29%)
Jun 3, 2026, 3:30 PM JST
PeptiDream Employees
PeptiDream had 645 employees as of December 31, 2025. The number of employees increased by 24 or 3.86% compared to the previous year.
Employees
645
Change
24
Growth
3.86%
Revenue / Employee
29.54M JPY
Profits / Employee
-5.53M JPY
Market Cap
133.41B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 645 | 24 | 3.86% |
| Sep 30, 2025 | 756 | 21 | 2.86% |
| Jun 30, 2025 | 757 | 12 | 1.61% |
| Mar 31, 2025 | 736 | 36 | 5.14% |
| Dec 31, 2024 | 621 | 18 | 2.99% |
| Sep 30, 2024 | 735 | 31 | 4.40% |
| Jun 30, 2024 | 745 | 53 | 7.66% |
| Mar 31, 2024 | 700 | 30 | 4.48% |
| Dec 31, 2023 | 603 | 34 | 5.98% |
| Sep 30, 2023 | 704 | 34 | 5.07% |
| Jun 30, 2023 | 692 | 53 | 8.29% |
| Mar 31, 2023 | 670 | 31 | 4.85% |
| Dec 31, 2022 | 569 | 392 | 221.47% |
| Sep 30, 2022 | 670 | 501 | 296.45% |
| Mar 31, 2022 | 639 | 481 | 304.43% |
| Dec 31, 2021 | 177 | 27 | 18.00% |
| Sep 30, 2021 | 169 | 23 | 15.75% |
| Jun 30, 2021 | 175 | 38 | 27.74% |
| Mar 31, 2021 | 158 | 34 | 27.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Takara Bio | 1,779 |
| GNI Group | 990 |
| Nxera Pharma | 354 |
| Japan Tissue Engineering | 204 |
| Healios K.K. | 75 |
| Cuorips | 56 |
| AnGes | 56 |
| StemRIM | 45 |
PeptiDream News
- 21 days ago - PeptiDream Quarterly report: Q1 2026 - Filings
- 6 weeks ago - PeptiDream announces initiation of Phase 1 clinical trial of AK1940 - TheFly
- 6 weeks ago - PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner - Business Wire
- 2 months ago - PeptiDream downgraded to Neutral from Buy at Citi - TheFly
- 3 months ago - PeptiDream Earnings Call Transcript: Q4 2025 - Transcripts
- 3 months ago - PeptiDream Quarterly report: Q4 2025 - Filings
- 3 months ago - PeptiDream Slides: Q4 2025 - Filings
- 4 months ago - Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan - GlobeNewsWire